| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
Purity: =98.50%
| Targets |
CHAPS does not have a specific pharmacological target. It is a biochemical reagent used to solubilize membrane proteins and disrupt protein-protein interactions. Its mechanism of action is based on its detergent properties, which allow it to interact with hydrophobic regions of membrane proteins and lipids, forming micelles that solubilize membrane components.
|
|---|---|
| ln Vitro |
CHAPS (0.5 %) can maintain the complex between DNA and DNA-binding factors (such as AP-1, SPI, GATA-1 and alpha regulatory factor ISGF3) and retain its biological activity [2]. CHAPS suppresses mononucleosome dissociation at subnanomolar doses of cytokines [2].
In vitro, CHAPS is used as a non-denaturing zwitterionic detergent for the solubilization of membrane proteins. It is effective at disrupting cell membranes and solubilizing membrane proteins while preserving their native conformation and activity. It is also used for denaturing cell lysis and extracting RNA and DNA. Its mild, non-denaturing properties make it suitable for sensitive biochemical assays. |
| ln Vivo |
In vivo, CHAPS is not administered as a therapeutic agent. Its utility is limited to in vitro applications such as protein solubilization, cell lysis, and biochemical assays. It is not used in vivo for pharmacological purposes.
|
| Enzyme Assay |
In vitro assays with CHAPS involve the solubilization of membrane proteins from cell membranes or tissue homogenates. Samples are incubated with CHAPS at concentrations typically ranging from 0.1% to 2% (w/v) in buffer. The detergent disrupts lipid bilayers and solubilizes membrane proteins, which can then be analyzed by SDS-PAGE, Western blotting, or used in functional assays such as enzyme activity measurements or receptor binding studies.
|
| Cell Assay |
CHAPS is used in cell lysis buffers for the extraction of proteins, RNA, and DNA from cultured cells. Cells are harvested and lysed in buffer containing CHAPS at concentrations of 0.5-2% (w/v) along with protease and nuclease inhibitors. The lysate is centrifuged, and the supernatant containing solubilized proteins, RNA, or DNA is collected for downstream applications such as immunoprecipitation, Western blotting, or PCR.
|
| Animal Protocol |
CHAPS is not used in in vivo animal studies as a therapeutic agent. It may be used in ex vivo applications for the solubilization of proteins from tissues harvested from animal studies.
|
| ADME/Pharmacokinetics |
CHAPS is a biochemical reagent and does not have pharmacokinetic properties as a drug. It is not administered systemically.
|
| Toxicity/Toxicokinetics |
CHAPS is a biochemical reagent and is not intended for human consumption. It may cause skin and eye irritation. Standard laboratory safety precautions should be followed.
|
| References | |
| Additional Infomation |
3-[(3-cholamidopropyl)dimethylammonium]propane-1-sulfonate is an ammonium betaine. It is functionally related to cholic acid. It is the conjugate base of 3-[(cholamidopropyl)dimethylammonium]-1-propanesulfonate.
CHAPS is a non-denaturing zwitterionic detergent used for solubilizing membrane proteins. It has a molecular weight of 614.88 and formula C₃₂H₅₈N₂O₇S. It is not a drug and has no clinical approval. |
| Molecular Formula |
C32H58N2O7S
|
|---|---|
| Molecular Weight |
614.8771
|
| Exact Mass |
614.396
|
| CAS # |
75621-03-3
|
| Related CAS # |
CHAPS hydrate;331717-45-4
|
| PubChem CID |
107670
|
| Appearance |
White to off-white solid powder
|
| Density |
1.01 g/mL at 20ºC
|
| Melting Point |
156-158ºC
|
| Index of Refraction |
1.6900 (estimate)
|
| LogP |
-4.32
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
42
|
| Complexity |
1030
|
| Defined Atom Stereocenter Count |
11
|
| SMILES |
C[C@H](CCC(=O)NCCC[N+](C)(C)CCCS(=O)(=O)[O-])[C@H]1CC[C@@H]2[C@@]1([C@H](C[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)O)C
|
| InChi Key |
UMCMPZBLKLEWAF-BCTGSCMUSA-N
|
| InChi Code |
InChI=1S/C32H58N2O7S/c1-21(8-11-29(38)33-14-6-15-34(4,5)16-7-17-42(39,40)41)24-9-10-25-30-26(20-28(37)32(24,25)3)31(2)13-12-23(35)18-22(31)19-27(30)36/h21-28,30,35-37H,6-20H2,1-5H3,(H-,33,38,39,40,41)/t21-,22+,23-,24-,25+,26+,27-,28+,30+,31+,32-/m1/s1
|
| Chemical Name |
3-[dimethyl-[3-[[(4R)-4-[(3R,5S,7R,8R,9S,10S,12S,13R,14S,17R)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]propyl]azaniumyl]propane-1-sulfonate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~83.33 mg/mL (~135.52 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 10 mg/mL (16.26 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6263 mL | 8.1317 mL | 16.2633 mL | |
| 5 mM | 0.3253 mL | 1.6263 mL | 3.2527 mL | |
| 10 mM | 0.1626 mL | 0.8132 mL | 1.6263 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA